Imdevimab Completed Phase 3 Trials for Healthy Volunteers (HV) / Coronavirus Disease 2019 (COVID‑19) Treatment

CompletedTreatment3 IdentifierTitleDrugs
NCT04452318COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay